BioMarin Pharmaceutical I... (BM8.DE)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
63.52
0.58 (0.92%)
At close: Dec 11, 2024, 2:43 PM
undefined% (undefined)
Bid | n/a |
Market Cap | 12.06B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.7 |
PE Ratio (ttm) | 90.74 |
Forward PE | n/a |
Analyst | n/a |
Ask | n/a |
Volume | 0 |
Avg. Volume (20D) | 14.1 |
Open | 63.02 |
Previous Close | 62.94 |
Day's Range | 63.02 - 63.52 |
52-Week Range | 58.04 - 90.70 |
Beta | undefined |
About BM8.DE
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2022
Employees 3,401
Stock Exchange XETRA
Ticker Symbol BM8.DE
Website https://www.biomarin.com